Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
US6169093A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jul 7, 1999 |
| Grant date | Jan 2, 2001 |
| Priority date | — |
| Expiry date | Jul 7, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds of formula I, ##STR1## wherein PA1 R.sup.1 represents C.sub.1-4 alkoxy optionally substituted by one or more fluorine atoms; PA1 R.sup.2 represents H or C.sub.1-6 alkoxy optionally substituted by one or more fluorine atoms; PA1 R.sup.3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted; PA1 R.sup.4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; PA1 X represents CH or N; and PA1 L is absent, or represents a cyclic group of formula Ia, ##STR2## or represents a chain of formula Ib, ##STR3## and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.